Clinical Trial Update: A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 pediatric trial evaluating autologous CD19-directed CAR-T cells for relapsed CD19-positive acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19-directed autologous CAR-T cells (CAR-T therapy targeting CD19)

Snippet

Sponsor: Seattle Children's Hospital | Conditions: B Cell Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING